StemSpine uses a patient’s bone marrow aspirate for treating back pain, according to a Feb. 14 news release. Three-year data found a continued efficacy rate of 87 percent with no patients needing re-dosage or surgical intervention. There were no safety-related concerns reported.
“To our knowledge, this pilot is the first demonstration of the clinical efficacy of injecting bone marrow aspirate in areas surrounding the disc, thereby potentially repairing, remodeling and improving the blood supply around the disc and lower back area,” Creative Medical Technology Holdings President and CEO Timothy Warbington said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
